Pfizer Inc. [NYSE: PFE] stock went on a downward path that fall over -0.06% on Monday, amounting to a one-week price increase of more than 0.08%. The company report on April 2, 2021 that Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021.
Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of a presentation and conference call with investment analysts at 10 a.m. EDT on Friday, April 9, 2021. Pfizer Oncology leadership will provide an update on the Oncology pipeline progress, specifically how the company is applying its capabilities to move quickly and utilize cutting-edge science to key programs such as LORBRENA® (lorlatinib) in ALK-positive metastatic lung cancer, elranatamab (PF-06863135) in multiple myeloma and our next generation breast cancer portfolio.
To access the live webcast, including audio, video and presentation slides, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning. Participants are advised to register in advance.
Over the last 12 months, PFE stock rose by 16.47%. The one-year Pfizer Inc. stock forecast points to a potential upside of 10.51. The average equity rating for PFE stock is currently 2.60, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $201.99 billion, with 5.58 billion shares outstanding and 5.57 billion shares in the current float. Compared to the average trading volume of 33.09M shares, PFE stock reached a trading volume of 22063268 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $40.54 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
DZ Bank have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 04, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $43 to $42. The new note on the price target was released on December 16, 2020, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise to $40, while Goldman analysts kept a Neutral rating on PFE stock.
The Average True Range (ATR) for Pfizer Inc. is set at 0.57, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 4.82. The Price to Book ratio for the last quarter was 3.10, with the Price to Cash per share for the same quarter was set at 2.20. Price to Free Cash Flow for PFE in the course of the last twelve months was 54.43 with Quick ratio for the last quarter at 1.00.
PFE Stock Performance Analysis:
Pfizer Inc. [PFE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.08. With this latest performance, PFE shares gained by 6.08% in over the last four-week period, additionally plugging by 5.26% over the last 6 months – not to mention a rise of 16.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 60.27, with the RSI for the last a single of trading hit 62.23, and the three-weeks RSI is set at 57.06 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 35.17, while it was recorded at 36.31 for the last single week of trading, and 36.54 for the last 200 days.
Insight into Pfizer Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +21.52 and a Gross Margin at +71.21. Pfizer Inc.’s Net Margin is presently recorded at +16.67.
Return on Total Capital for PFE is now 8.14, given the latest momentum, and Return on Invested Capital for the company is 6.93. Return on Equity for this stock inclined to 11.05, with Return on Assets sitting at 4.34. When it comes to the capital structure of this company, Pfizer Inc. [PFE] has a Total Debt to Total Equity ratio set at 65.26. Additionally, PFE Total Debt to Total Capital is recorded at 39.49, with Total Debt to Total Assets ending up at 26.76. Long-Term Debt to Equity for the company is recorded at 60.48, with the Long-Term Debt to Total Capital now at 36.60.
Reflecting on the efficiency of the workforce at the company, Pfizer Inc. [PFE] managed to generate an average of $88,981 per employee. Receivables Turnover for the company is 5.03 with a Total Asset Turnover recorded at a value of 0.26.Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.40.
PFE Stock EPS
With the latest financial reports released by the company, Pfizer Inc. posted 0.8/share EPS, while the average EPS was predicted by analysts to be reported at 0.73/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to 10.07%.
Pfizer Inc. [PFE] Insider Position Details
There are presently around $134,156 million, or 67.60% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 447,958,747, which is approximately -0.691% of the company’s market cap and around 0.04% of the total institutional ownership; BLACKROCK INC., holding 396,973,512 shares of the stock with an approximate value of $14.4 billion in PFE stocks shares; and STATE STREET CORP, currently with $10.14 billion in PFE stock with ownership of nearly -3.29% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 1,550 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 127,428,601 shares. Additionally, 1,035 investors decreased positions by around 250,799,816 shares, while 181 investors held positions by with 3,319,565,928 shares. The mentioned changes placed institutional holdings at 3,697,794,345 shares, according to the latest SEC report filing. PFE stock had 282 new institutional investments in for a total of 17,931,919 shares, while 113 institutional investors sold positions of 22,560,763 shares during the same period.